JP6487419B2 - Ｔａｆａ４化合物及び疼痛を処置するためのその使用 - Google Patents

Ｔａｆａ４化合物及び疼痛を処置するためのその使用 Download PDF

Info

Publication number
JP6487419B2
JP6487419B2 JP2016512345A JP2016512345A JP6487419B2 JP 6487419 B2 JP6487419 B2 JP 6487419B2 JP 2016512345 A JP2016512345 A JP 2016512345A JP 2016512345 A JP2016512345 A JP 2016512345A JP 6487419 B2 JP6487419 B2 JP 6487419B2
Authority
JP
Japan
Prior art keywords
pain
tafa4
neurons
protein
mice
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2016512345A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016519138A5 (enExample
JP2016519138A (ja
Inventor
モクリッチ，アジズ
デルフィーニ，マリー−クレール
マンティッレリ，アナベル
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aix Marseille Universite
Centre National de la Recherche Scientifique CNRS
Original Assignee
Aix Marseille Universite
Centre National de la Recherche Scientifique CNRS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aix Marseille Universite, Centre National de la Recherche Scientifique CNRS filed Critical Aix Marseille Universite
Publication of JP2016519138A publication Critical patent/JP2016519138A/ja
Publication of JP2016519138A5 publication Critical patent/JP2016519138A5/ja
Application granted granted Critical
Publication of JP6487419B2 publication Critical patent/JP6487419B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/195—Chemokines, e.g. RANTES
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A01K67/0276—Knock-out vertebrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/07—Animals genetically altered by homologous recombination
    • A01K2217/075—Animals genetically altered by homologous recombination inducing loss of function, i.e. knock out
    • A01K2217/077—Animals genetically altered by homologous recombination inducing loss of function, i.e. knock out heterozygous knock out animals displaying phenotype
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/035—Animal model for multifactorial diseases
    • A01K2267/0356—Animal model for processes and diseases of the central nervous system, e.g. stress, learning, schizophrenia, pain, epilepsy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Environmental Sciences (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Molecular Biology (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Animal Husbandry (AREA)
  • Biotechnology (AREA)
  • Anesthesiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2016512345A 2013-05-06 2014-05-06 Ｔａｆａ４化合物及び疼痛を処置するためのその使用 Active JP6487419B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP13305592.1 2013-05-06
EP13305592.1A EP2801369A1 (en) 2013-05-06 2013-05-06 TAFA4 compounds and uses thereof for treating pain
PCT/EP2014/059247 WO2014180853A1 (en) 2013-05-06 2014-05-06 Tafa4 compounds and uses thereof for treating pain

Publications (3)

Publication Number Publication Date
JP2016519138A JP2016519138A (ja) 2016-06-30
JP2016519138A5 JP2016519138A5 (enExample) 2018-08-30
JP6487419B2 true JP6487419B2 (ja) 2019-03-20

Family

ID=48428409

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016512345A Active JP6487419B2 (ja) 2013-05-06 2014-05-06 Ｔａｆａ４化合物及び疼痛を処置するためのその使用

Country Status (8)

Country Link
US (2) US9884088B2 (enExample)
EP (2) EP2801369A1 (enExample)
JP (1) JP6487419B2 (enExample)
CN (1) CN105209056B (enExample)
CA (2) CA2910652C (enExample)
DK (1) DK2994157T3 (enExample)
ES (1) ES2813629T3 (enExample)
WO (1) WO2014180853A1 (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016147825A1 (ja) * 2015-03-13 2016-09-22 シスメックス株式会社 被検物質の検出方法およびその方法に用いられる試薬キット
WO2019089465A1 (en) * 2017-10-30 2019-05-09 The Regents Of The University Of California Calibration free in-vivo measurement of analytes using electrochemical sensors
JP7171081B2 (ja) * 2018-04-24 2022-11-15 ニューラクル サイエンス カンパニー リミテッド 神経病性疼痛の治療のための配列類似性１９、メンバーａ５抗体を有する抗ファミリーの用途
ES2943136T3 (es) * 2018-09-27 2023-06-09 Inst Nat Sante Rech Med Polipéptido de TAFA4 para su uso para reducir la inflamación cutánea
CN109596818B (zh) * 2018-12-13 2024-03-19 丁蓉 一种基于电生理学分析当归四逆汤预防奥沙利铂神经毒性机制的研究方法
WO2021156310A1 (en) * 2020-02-04 2021-08-12 INSERM (Institut National de la Santé et de la Recherche Médicale) Tafa4 polypeptide or polynucleotide for treating inflammatory disease
JP7729824B2 (ja) * 2020-02-13 2025-08-26 ザ ユナイテッド ステイツ オブ アメリカ， アズ リプレゼンテッド バイ ザ セクレタリー デパートメント オブ ヘルス アンド ヒューマン サービシーズ マルガリン酸はｐｉｅｚｏ２媒介性疼痛を低減させる
EP4447991A1 (en) 2021-12-17 2024-10-23 Tafalgie Therapeutics Peptides and methods for use in treating pain
AU2022419489A1 (en) * 2021-12-20 2024-06-13 Amgen Inc. Dll3 binding peptides and uses thereof
AR129441A1 (es) 2022-05-25 2024-08-28 Tafalgie Therapeutics Péptidos y métodos para el tratamiento del dolor
CN119584981A (zh) * 2022-05-31 2025-03-07 纽洛可遗传学有限公司 用于治疗视网膜或黄斑疾病的组合物
KR20250153765A (ko) 2023-02-17 2025-10-27 나오스 인스티튜트 오브 라이프 사이언스 피부 내성 역치를 증가시킬 수 있는 생태생물학적 화합물의 선택 방법
WO2025116606A1 (ko) * 2023-11-30 2025-06-05 주식회사 뉴라클제네틱스 신규한 케모카인-유사 단백질 단편

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090077680A1 (en) * 2000-06-12 2009-03-19 Alejandro Abuin Genetically Engineered and Photyped Mice and Stem Cell Clones for Producing the Same
US20090136552A1 (en) * 2004-07-30 2009-05-28 Mette Gronborg Growth factors nsg28, nsg30, and nsg32

Also Published As

Publication number Publication date
ES2813629T3 (es) 2021-03-24
US20160113996A1 (en) 2016-04-28
CA3235916A1 (en) 2014-11-13
US9884088B2 (en) 2018-02-06
EP2994157A1 (en) 2016-03-16
EP2801369A1 (en) 2014-11-12
CN105209056A (zh) 2015-12-30
DK2994157T3 (da) 2020-08-24
CA2910652A1 (en) 2014-11-13
CA2910652C (en) 2024-05-28
WO2014180853A1 (en) 2014-11-13
EP2994157B1 (en) 2020-07-01
US20180110829A1 (en) 2018-04-26
JP2016519138A (ja) 2016-06-30
CN105209056B (zh) 2018-01-23

Similar Documents

Publication Publication Date Title
JP6487419B2 (ja) Ｔａｆａ４化合物及び疼痛を処置するためのその使用
US11642423B2 (en) Motor neuron-specific expression vectors
Kanwar et al. Simultaneous neuroprotection and blockade of inflammation reverses autoimmune encephalomyelitis
JP2017524382A (ja) 偽アレルギー薬物反応を検出するためおよび有害反応を予防する遮断薬を同定するためのｍｒｇｐｒｘ２／ｍｒｇｐｒｂ２発現細胞ベースのアッセイ
JP2013529181A (ja) 神経障害を治療するための組成物および方法
US10123983B2 (en) DNA methyltransferases for the treatment and prevention of arthritis
Shi et al. Activation of TGR5 in the injured nerve site according to a prevention protocol mitigates partial sciatic nerve ligation–induced neuropathic pain by alleviating neuroinflammation
Wang et al. Small G-protein Rheb gates mammalian target of rapamycin signaling to regulate morphine tolerance in mice
US11969460B2 (en) Methods and compositions for treating decreased cognitive ability
CN102648977B (zh) 滤泡素抑制素样蛋白1在调节钠钾atp酶活性中的用途
Class et al. Patent application title: TAFA4 COMPOUNDS AND USES THEREOF FOR TREATING PAIN Inventors: Aziz Moqrich (Marseille, FR) Marie-Claire Delfini (Marseille, FR) Annabelle Mantilleri (Apt, FR)
Kearney et al. Rit2 silencing in dopamine neurons drives a Parkinsonian phenotype
US10947311B2 (en) VCAM-1 mediated methods and compositions for treating aging-associated impairments
US10017765B2 (en) Inhibitors of CACNA1A/ALPHA1A subunit internal ribosomal entry site (IRES) and methods of treating spinocerebellar ataxia type 6
US11878012B2 (en) Compositions and methods for treating traumatic brain injury
US20250289906A1 (en) Modulation of extracellular kinase activity and function for treatment of pain and neurodegenerative/neuroimmune disease
Li Neuronal Interleukin-13 (IL-13) Modulates Synaptic Physiology and Neuronal Resilience to Trauma
Fuller An Investigation into Noxious Mechanosensation, and the Role of Peripheral Neuron Subpopulations in Pain
Ilaria et al. Voltage-independent GluN2A-type NMDA receptor Ca2+ signaling promotes audiogenic seizures, attentional and cognitive deficits in mice
KR20220025810A (ko) 스미스-마제니스 증후군을 치료하기 위한 방법 및 조성물
Gandhi Organisation of Glutamatergic Inputs to Central Amygdala
O'donnell Glutamate transport affects mitochondria and calcium signaling in astrocytic processes under normal and pathological conditions
Sharma Efficacy of a novel neuronal death inhibitor in Alzheimer’s disease models
Stucky SEX DIFFERENCES IN GENE EXPRESSION AND PAIN-RELATED BEHAVIORS IN A PRECLINICAL MODEL OF MIGRAINE

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20170421

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20180220

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20180521

A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20180720

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20181002

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20181213

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20181218

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20190129

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20190221

R150 Certificate of patent or registration of utility model

Ref document number: 6487419

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250